Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to Neutral Rating by Cantor Fitzgerald

Cantor Fitzgerald downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN - Free Report) from an overweight rating to a neutral rating in a report published on Wednesday morning, Marketbeat Ratings reports. They currently have $36.00 target price on the specialty pharmaceutical company's stock, down from their prior target price of $57.00.

Supernus Pharmaceuticals Trading Down 4.5 %

Supernus Pharmaceuticals stock traded down $1.54 during midday trading on Wednesday, reaching $33.05. The stock had a trading volume of 757,774 shares, compared to its average volume of 426,847. The company has a fifty day moving average price of $37.55 and a two-hundred day moving average price of $35.27. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The company has a market capitalization of $1.83 billion, a P/E ratio of 30.89 and a beta of 0.90.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of the business's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 9.30% of the stock is owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SUPN. Raiffeisen Bank International AG bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $42,000. Smartleaf Asset Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares during the last quarter. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at about $52,000. Finally, Headlands Technologies LLC lifted its position in shares of Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,015 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.